Cancer Chemotherapy and Pharmacology

, Volume 31, Issue 1, pp 18–22 | Cite as

Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment

  • Norbert Marschner
  • Jochem Kötting
  • Hansjörg Eibl
  • Clemens Unger
Original Articles Hexadecylphospho Choline Alkyllysophospholipids Alkylphosphocholines Biodistributior


The distribution of the alkylphosphocholine hexadecylphosphocholine (He-PC) and the (alkyl)lysophospholipid 1-0-octadecyl-2-0-methyl-rac-glycero-3-phosphocholine (ET18-OCH3) was analyzed in rats. The compounds were given orally at a daily dose of 75 μmol/kg body weight. After 6, 11, and 18 days, three rats in each treatment group were killed and the drug concentration in various tissues and fluids was determined. With the exception of the kidney (He-PC) and brain (He-PC and ET18-OCH3), steady-state levels of the drugs could be achieved in all organs investigated and in serum. Maximal concentrations of He-PC were found in the kidney, adrenal glands, and spleen, whereas the highest concentrations of ET18-OCH3 were detected in the adrenal glands, spleen, and small intestine. The concentrations of He-PC exceeded those of ET18-OCH3 in most tissues by a factor of about 2–25. Since samples of urine and feces did not contain detectable amounts of the compounds, the absorption of both lipid analogues was assumed to be complete. The total amount of He-PC recovered after 6, 11, and 18 days was 15%, 12%, and 6%, respectively, and that of ET18-OCH3 was 1.3%, 0.8%, and 0.3%, respectively. This indicates that the bioavailability of He-PC and ET18-OCH3 is not controlled by differences in the uptake of the two drugs, but by differences in their metabolism. The results could explain the differing efficacy of these two compounds in their antitumor action in animal models.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andreesen R, Osterholz J, Luckenbach A, Costabel U, Schulz A, Speth V, Munder PG, Löhr GW (1984) Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J Natl Cancer Inst 72:53–58Google Scholar
  2. 2.
    Berger MR, Munder PG, Schmähl D, Westphal O (1984) Influence of the alkyl-lysophospholipid ET-18-OCH3 on methylnitrosourea-induced rat mammary carcinomas. Oncology 41:109–113Google Scholar
  3. 3.
    Berger MR, Muschiol C, Schmähl D, Unger C, Eibl H (1987) Chemotherapeutische Studien zur Struktur-Wirkungs-Beziehung zytotoxischer Alkyllysophospholipide an chemisch induzierten Mammakarzinomen der Ratte. In: Unger C, Eibl H, Nagel GA (eds) Die Zellmembran als Angriffspunkt der Tumortherapie. Zuckschwerdt, München, pp 27–36Google Scholar
  4. 4.
    Breiser A, Kim DJ, Fleer EAM, Damenz W, Drube A, Berger M, Nagel GA, Eibl H, Unger C (1987) Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 22:925–926Google Scholar
  5. 5.
    Eibl H, Engel J (1992) Synthesis of hexadecylphosphocholine. Prog Exp Tumor Res 34 (in press)Google Scholar
  6. 6.
    Eibl H, Woolley P (1986) Synthesis of enantiomerically pure glycerolesters and ethers: I. Methods employing the precursor 1,2-isopropylidene-sn-glycerol. Chem Phys Lipids 41:53–63Google Scholar
  7. 7.
    Fleer EAM, Kim DJ, Unger C, Eibl H (1986) 1-0-Octadecyl-2-0-methyl-rac-glycero-3-phospho-(3H-methyl)-choline: chemical preparation and metabolism in leukemia Raji cells. In: Muccino RR (ed) Proceedings of the Second International Symposium, Kansas City, 3–6 September 1985. Elsevier, Amsterdam, pp 473–478Google Scholar
  8. 8.
    Fleer EAM, Unger C, Kim DJ, Eibl H (1987) Metabolism of ether phospholipids and analogs in neoplastic cells. Lipids 22:856–861Google Scholar
  9. 9.
    Fleer EAM, Kim DJ, Nagel GA, Eibl H, Unger C (1990) Cytotoxic activity of lysophosphatidylcholine analogues on human lymphoma Raji cells. Onkologie 13:295–300Google Scholar
  10. 10.
    Helferman DM, Barnes KC, Kinkade JM, Vogler WR, Shoji M, Kuo JF (1983) Phospholipid-sensitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipid. Cancer Res 43: 2955–2961Google Scholar
  11. 11.
    Herrmann DBJ (1985) Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl-lysophospholipid analogues. J Natl Cancer Inst 75:423–430Google Scholar
  12. 12.
    Herrmann DBJ, Munder PG (1986) Pharmacokinetics of cytotoxic ether phospholipids. Proceedings, 2nd International Conference on PAF and Structurally Related Alkyl Lipids, Gatlinburg, Tennessee, October 26–29, p 156Google Scholar
  13. 13.
    Herrmann DBG, Besenfelder E, Bicker U, Pahlke W, Böhm E (1987) Pharmacokinetics of the thioether phospholipid analogue BM 41.440 in rats. Lipids 22:952–957Google Scholar
  14. 14.
    Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H, Unger C, Berger MR (1988) Characterization of the antitumor activity of hexadecylphosphocholine (D-18 506). Eur J Cancer Clin Oncol 24:1457–1461Google Scholar
  15. 15.
    Hilgard P, Harlemann JH, Voegeli R, Maurer HR, Echarti C, Unger C (1989) The antineoplastic activity of hexadecylphosphocholine (HPC) is associated with tumor cell differentiation (abstract 2310). Proc Am Assoc Cancer Res 30:580Google Scholar
  16. 16.
    Hilgard P, Kampherm E, Nolan L, Pohl J, Reissmann T (1992) Investigation into the immunological effects of Milteforsine, a new anticancer agent under development. J Cancer Res Clin Oncol 117 (in press)Google Scholar
  17. 17.
    Hilgard P, Stekar J, Harlemann H (1992) Experimental therapeutic studies with Miltefosine in rats and mice. Prog Exp Tumor Res 34 (in press)Google Scholar
  18. 18.
    Hochhuth C, Berkovic D, Eibl H, Unger C, Doenecke D (1990) Effects of antineoplastic phospholipids on parameters of cell differentiation in U 937 cells. J Cancer Res Clin Oncol 116:459–466Google Scholar
  19. 19.
    Modolell M, Andreesen R, Pahlke W, Brugger U, Munder PG (1979) Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res 39:4681–4686Google Scholar
  20. 20.
    Munder PG, Weltzien HU, Modolell M (1976) Lysolecithin analogs: a new class of immunopotentiators. In: Miescher PA (ed) Proceedings of the 7th International Symposium on Immunopathology. Schwabe, Basel, pp 411–424Google Scholar
  21. 21.
    Muschiol C, Berger MR, Schuler B, Scherf HR, Garzon FT, Zeller WJ, Unger C, Eibl H, Schmähl D (1987) Alkylphosphocholines: toxicity and anticancer properties. Lipids 22:930–934Google Scholar
  22. 22.
    Oishi K, Raynor RL, Charp PA, Kuo JF (1988) Regulation of protein kinase C by lysophospholipids. J Biol Chem 263:6865–6871Google Scholar
  23. 23.
    Rustenbeck J, Lenzen S (1990) Quantitation of a new antineoplastic agent, hexadecylphosphocholine. Arch Pharmacol [Suppl] 341: R111Google Scholar
  24. 24.
    Schallier DK, Bruyneel EA, Storme GA, Hilgard P, Marcel MM (1990) Hexadecylphosphocholine inhibits invasion of a mouse fibrosarcoma cell line MO4 in vitro (abstract 405). Proc Am Assoc Cancer Res 31:68Google Scholar
  25. 25.
    Seewald MJ, Olsen RA, Sehgal I, Melder DC, Modest EJ, Powis G (1990) Inhibition of growth factor-dependent inositol phosphate Ca2+ signalling by antitumor ether lipid analogues. Cancer Res 50: 4458–4463Google Scholar
  26. 26.
    Snyder F, Record M, Smith Z, Blank ML, Hoffmann DR (1987) Mechanistic studies related to their metabolism, subcellular localization, effects on cellular transport systems. In: Unger C, Eibl H, Nagel GA (eds) Die Zellmembran als Angriffspunkt der Tumortherapie. Zuckschwerdt, München, pp 19–26Google Scholar
  27. 27.
    Storme GA, Bruyneel EA, Schallier DC, Bolscher JG, Berdel WE, Mareel MM (1987) Effects of lipid derivatives on invasion in vitro and on surface glycoproteins of three rodent cell types. Lipids 22: 847–850Google Scholar
  28. 28.
    Touchstone JC, Levin SS, Dohins MF, Carter PJ (1981) Differentiation of saturated and unsaturated phospholipids on thin layer chromatograms. J High Resol Chromatogr Commun 4:423–426Google Scholar
  29. 29.
    Unger C, Fleer EAM, Damenz W, Hilgard P, Nagel G, Eibl H (1991) Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediators 3:71–78Google Scholar
  30. 30.
    Venditti JM (1981) Preclinical drug development: rationale and methods. Semin Oncol 8:349–361Google Scholar
  31. 31.
    Zheng B, Oiski K, Shoja M, Eibl H, Berdel WE, Hajdu J, Vogler WR, Kuo JF (1990) Inhibition of protein kinase C (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res 50:3025–3031Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Norbert Marschner
    • 1
  • Jochem Kötting
    • 2
  • Hansjörg Eibl
    • 2
  • Clemens Unger
    • 1
  1. 1.Division of Hematology/Oncology, Department of Internal MedicineUniversity HospitalGöttingenFederal Republic of Germany
  2. 2.Max-Planck-Institute for Biophysical ChemistryGöttingenFederal Republic of Germany

Personalised recommendations